Real-world outcomes of insulin pump compared to multiple daily injection therapy in adult type 1 diabetes mellitus patients in a Mediterranean scenario
| Autor: | José Alberto García-Seco, Angela María Seco, Miriam Herrera-Moraleda, Jesús Moreno-Ferández, José Ramón Muñoz-Rodríguez |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Insulin pump
medicine.medical_specialty business.industry Endocrinology Diabetes and Metabolism Insulin medicine.medical_treatment 030209 endocrinology & metabolism Hypoglycemia medicine.disease Gastroenterology Clinical trial 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry Internal medicine Diabetes mellitus Cohort Internal Medicine Medicine 030212 general & internal medicine Glycated hemoglobin business Glycemic |
| Zdroj: | International Journal of Diabetes in Developing Countries. 41:259-265 |
| ISSN: | 1998-3832 0973-3930 |
| DOI: | 10.1007/s13410-020-00887-4 |
| Popis: | To analyze the real-life outcomes of insulin pump therapy, as compared to multiple daily injection (MDI) treatment, in adult type 1 diabetes mellitus (T1DM) patients from a tertiary diabetes care hospital in a Mediterranean scenario. Observational cross-sectional study regarding all T1DM patients on insulin pump therapy compared (1:1) with MDI-treated patients selected through simple random sampling from our database. Primary efficacy outcome was to describe glycated hemoglobin A1c (HbA1c) differences. Ninety patients were analyzed (male 53%). Mean age was 40.0 ± 14.4 years, and T1DM duration was 19.7 ± 11.8 years. Duration of continuous subcutaneous insulin infusion (CSII) therapy was 5.6 ± 3.9 years, and most frequent indication (47%) for CSII treatment was HbA1c ≥ 53 mmol/mol (7%). More patients treated with CSII used interstitial glucose monitoring compared with MDI patients (73% vs. 20%, p < 0.001). Self-monitoring of blood glucose (SMBG) daily frequency was higher among insulin pump–treated patients compared with patients receiving MDI therapy (5.0 ± 2.2 times/day vs. 3.8 ± 3.2 times/day, p = 0.048). Glycated hemoglobin was lower among patients on insulin pump therapy compared with MDI-treated patients (54 ± 10 mmol/mol vs. 60 ± 13 mmol/mol, 7.1 ± 0.9% vs. 7.6 ± 1.2%; p = 0.038). Besides, patients on insulin pump showed less hypoglycemia frequency (6% vs. 11%, p = 0.006) and suffered less from frequent hypoglycemia (20% vs. 42%, p = 0.02). Patients using insulin pump therapy had a better glycemic control relative to the injection therapy cohort in a real-world Mediterranean scenario. Clinical Trials NCT03793283. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink